Identification of biomarkers for colorectal cancer through proteomics-based approaches

Expert Review of Proteomics

Volumn 7, Issue 6, 2010, Pages 879-895

  Tjalsma, Harold ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cancer; colorectal cancer; diagnostics; mass spectrometry; proteomics

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ALPHA 1 ANTITRYPSIN; ALPHA DEFENSIN; ANTIBODY; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; CALCYCLIN; CALGRANULIN A; CALGRANULIN B; CARCINOEMBRYONIC ANTIGEN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; FETUIN A; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLUCOSE REGULATED PROTEIN 78; INTERCELLULAR ADHESION MOLECULE 1; LAMIN A; LAMIN C; MITOGEN ACTIVATED PROTEIN KINASE 3; MOLECULAR MARKER; MUCIN 1; MUCIN 5AC; NUCLEAR MATRIX PROTEIN 22; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN; PROTEINASE; SELENIUM BINDING PROTEIN; TRANSFERRIN; TRANSGELIN; TUMOR ANTIGEN; UNINDEXED DRUG;

ANTIBODY BLOOD LEVEL; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER TISSUE; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING;

ANIMALS; COLORECTAL NEOPLASMS; FECES; HUMANS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650485809     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.10.81     Document Type: Review

References (112)

1. Jass JR, Morson BC. Reporting colorectal cancer. J. Clin. Pathol. 40, 1016-1023 (1987).
2. Booth RA. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 249, 87-96 (2007). (Pubitemid 46437280)
3. Simon J. Should all people over the age of 50 have regular fecal occult-blood tests? Postpone population screening until problems are solved. N. Engl. J. Med. 338, 1151-1152 (1998). (Pubitemid 28227489)
4. Lieberman D. Clinical practice. Screening for colorectal cancer. N. Engl. J. Med. 361, 1179-1187 (2009).
5. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J. Clin. 59, 366-378 (2009).
6. Vogelstein B, Kinzler KW. Digital PCR. Proc. Natl Acad. Sci. USA 96, 9236-9241 (1999). (Pubitemid 29374738)
7. Melotte V, Lentjes M, van den Bosch S et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J. Natl. Cancer Inst. 101, 916-927 (2009).
8. Nagasaka T, Tanaka N, Cullings HM et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J. Natl. Cancer Inst. 101, 1244-1258 (2009).
9. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg. Oncol. (Oxf.) 18, 15-24 (2009).
10. Duffy MJ, van Dalen A, Haglund C et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer 43, 1348-1360 (2007). (Pubitemid 46874070)
11. Huerta S. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev. Mol. Diagn. 8, 277-288 (2008). (Pubitemid 351724707)
12. Sagynaliev E, Steinert R, Nestler G, Lippert H, Knoch M, Reymond MA. Web-based data warehouse on gene expression in human colorectal cancer. Proteomics 5, 3066-3078 (2005). (Pubitemid 41176473)
13. Reymond MA, Steinert R, Kahne T, Sagynaliev E, Allal AS, Lippert H. Expression and functional proteomics studies in colorectal cancer. Pathol. Res. Pract. 200, 119-127 (2004). (Pubitemid 38950441)
14. Barderas R, Babel I, Casal JI. Colorectal cancer proteomics molecular characterization and biomarker discovery. Proteomics Clin. Appl. 4, 159-178 (2010).
15. OFarrell P. The pre-omics era: the early days of two-dimensional gels. Proteomics 8(23-24), 4842-4852 (2008).
16. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002). (Pubitemid 34178440)
17. Issaq HJ, Xiao Z, Veenstra TD. Serum and plasma proteomics. Chem. Rev. 107, 3601-3620 (2007). (Pubitemid 47333550)
18. Mehta AI, Ross S, Lowenthal MS et al. Biomarker amplification by serum carrier protein binding. Dis. Markers 19, 1-10 (2003). (Pubitemid 38125650)
19. Seam N, Gonzales DA, Kern SJ, Hortin GL, Hoehn GT, Suffredini AF. Quality control of serum albumin, depletion for proteomic analysis. Clin. Chem. 53, 1915-1920 (2007). (Pubitemid 350036035)
20. Hu LH, Ye ML, Zou HF. Recent advances in mass spectrometry-based peptidome analysis. Expert Rev. Proteomics 6, 433-447 (2009).
21. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev. Cancer 6, 961-967 (2006). (Pubitemid 44862680)
22. Villanueva J, Martorella AJ, Lawlor K et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 5, 1840-1852 (2006). (Pubitemid 44688193)
23. Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Temps P. A sequence-specific exopeptidase activity test (SSEAT) for functional biomarker discovery. Mol. Cell. Proteomics 7, 509-518 (2008). (Pubitemid 351472461)
24. Peccerella T, Lukan N, Hofheinz R et al. Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology. Clin. Chem. 56, 272-280 (2010).
25. Dekker LJ, Burgers PC, Charif H et al. Differential expression of protease activity in serum samples of prostate carcinoma patients with metastases. Proteomics 10(12), 2348-2358 (2010).
26. Check E. Proteomics and cancer - running before we can walk? Nature 429, 496-497 (2004).
27. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl. Cancer Inst. 97, 307-309 (2005).
28. Gast MC, van Gils CH, Wessels LFA et al. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Clin. Chem. Lab. Med. 47, 694-705 (2009).
29. Findeisen P, Neumaier M. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective. Clin. Chem. Lab. Med. 47, 666-684 (2009).
30. Wright GL. 2-dimensional acrylamide gel electrophoresis of cancer-patient serum proteins. Ann. Clin. Lab. Sci. 4, 281-293 (1974).
31. de Noo ME, Mertens BJA, Ozalp A et al. Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur. J. Cancer 42, 1068-1076 (2006). (Pubitemid 44631671)
32. de Noo ME, Tollenaar R, Deelder AM, Bouwman LH. Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World J. Gastroenterol. 12, 6594-6601 (2006). (Pubitemid 44794934)
33. Tuck MK, Chan DW, Chia D et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J. Proteome Res. 8, 113-117 (2009).
34. McLerran D, Grizzle WE, Feng ZD et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin. Chem. 54, 53-60 (2008). (Pubitemid 351182596)
35. McLerran D, Grizzle WE, Feng Z et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin. Chem. 54, 44-52 (2008). (Pubitemid 351182595)
36. Ward DG, Suggett N, Cheng Y et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer 94, 1898-1905 (2006). (Pubitemid 43882582)
37. Chen YD, Zheng S, Yu JK, Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin. Cancer Res. 10, 8380-8385 (2004). (Pubitemid 40053400)
38. Yu J, Chen Y, Zheng S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J. Gastroenterol. 10, 3127-3131 (2004). (Pubitemid 39419872)
39. Liu X, Shen J, Li Z, Yan L, Gu J. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest. 24, 747-753 (2006). (Pubitemid 44949879)
40. Ward DG, Nyangoma S, Joy H et al. Proteomic profiling of urine for the detection of colon cancer. Proteome Sci. 6, 19 (2008). (Pubitemid 351935851)
41. Ward DG, Roberts K, Brookes MJ et al. Increased hepcidin expression in colorectal carcinogenesis. World J. Gastroenterol. 14, 1339-1345 (2008). (Pubitemid 351425211)
42. Kemna E, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica 93, 90-97 (2008). (Pubitemid 351156156)
43. Schlosser G, Pocsfalvi G, Huszar E, Malorni A, Hudecz F. MALDI-TOF mass spectrometry of a combinatorial peptide library: effect of matrix composition on signal suppression. J. Mass Spectrom. 40, 1590-1594 (2005). (Pubitemid 43048629)
44. Szajli E, Feher T, Medzihradszky KF. Investigating the quantitative nature of MALDI-TOF MS. Mol. Cell. Proteomics 7, 2410-2418 (2008).
45. Wang Q, Shen J, Li ZF et al. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 9, 287 (2009).
46. Swinkels DW, Girelli D, Laarakkers C et al. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PloS ONE 3(7), e2706 (2008).
47. Quaresima B, Crugliano T, Gaspari M et al. A proteomics approach to identify changes in protein profiles in serum of Familial adenomatous polyposis patients. Cancer Lett. 272, 40-52 (2008).
48. Hung KE, Kho AT, Sarracino D et al. Mass spectrometry-based study of the plasma proteome in a mouse intestinal tumor model. J. Proteome Res. 5, 1866-1878 (2006). (Pubitemid 44235755)
49. Kocer B, McKolanis J, Soran A. Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma. BMC Gastroenterol. 6, 4 (2006). (Pubitemid 43240139)
50. Silk AW, Schoen RE, Potter DM, Finn OJ. Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol. Immunol. 47, 52-56 (2009).
51. Bresalier RS, Byrd JC, Tessler D et al. A circulating ligand for galectin-3 glycoprotein elevated in individual is a haptoglobin-related with colon cancer. Gastroenterology 127, 741-748 (2004). (Pubitemid 39208407)
52. Arredondo M, Kloosterman J, Nunez S et al. Heme iron uptake by Caco-2 cells is a saturable, temperature sensitive and modulated by extracellular pH and potassium. Biological Trace Element Res. 125, 109-119 (2008).
53. Peng JY, Zhang QF, Ma YL et al. A rat-to-human search for proteomic alterations reveals transgelin as a biomarker relevant to colorectal carcinogenesis and liver metastasis. Electrophoresis 30, 2976-2987 (2009).
54. Xing PX, Young GP, Ho D, Sinatra MA, Hoj PB, McKenzie IF. A new approach to fecal occult blood testing based on the detection of haptoglobin. Cancer 78, 48-56 (1996). (Pubitemid 26189904)
55. Reuschenbach M, Kloor M, Morak M et al. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. Familial Cancer 9, 173-179 (2010).
56. Tjalsma H, Schaeps RM, Swinkels DW. Immunoproteomics: from biomarker discovery to diagnostic applications. Proteomics Clin. Appl. 2, 167-180 (2008). (Pubitemid 351284898)
57. He YJ, Mou ZR, Li WL et al. Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis. Int. J. Colorectal Dis. 24, 1271-1279 (2009).
58. Collart FR, Chubb CB, Mirkin BL, Huberman E. I Increased inosine-5- phosphate dehydrogenase gene-expression in solid tumor-tissues and tumor-cell lines. Cancer Res. 52, 5826-5828 (1992).
59. Ran YL, Hu H, Zhou Z et al. Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin. Cancer Res. 14, 2696-2700 (2008).
60. Babel I, Barderas R, Diaz-Uriarte R, Martinez-Torrecuadrada JL, Sanchez- Carbayo M, Casal JI. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol. Cell. Proteomics 8, 2382-2395 (2009).
61. Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr. Opin. Immunol. 7, 812-818 (1995). (Pubitemid 26038522)
62. Hausen HZ. Streptococcus bovis: causal or incidental involvement in cancer of the colon? Int. J. Cancer 119, XI-XII (2006).
63. Tjalsma H, Scholler-Guinard M, Lasonder E, Ruers TJ, Willems HL, Swinkels DW. Profiling the humoral immune response in colon cancer patients: diagnostic antigens from Streptococcus bovis. Int. J. Cancer 119, 2127-2135 (2006). (Pubitemid 44423671)
64. Boleij A, Roelofs R, Schaeps RM et al. Increased exposure to bacterial antigen RpL7/L12 in early stage colorectal cancer patients. Cancer 116(17), 4014-4022 (2010).
65. Abdulamir AS, Hafidh RR, Mahdi LK, Al-Jeboori T, Abubaker F. Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma. BMC Cancer 9, 403 (2009).
66. Ma YL, Peng JY, Liu WJ et al. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol. Cell. Proteomics 8, 1878-1890 (2009).
67. Bendtsen JD, Jensen LJ, Blom N, von Heijne G, Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng. Des. Sel. 17, 349-356 (2004). (Pubitemid 39093515)
68. Zhang YB, Ye YJ, Shen DH et al. Identification of transgelin-2 as a biomarker of colorectal cancer by laser capture microdissection and quantitative proteome analysis. Cancer Sci. 101, 523-529 (2010).
69. Tjalsma H, Pluk W, van den Heuvel LP, Peters WH, Roelofs R, Swinkels DW. Proteomic inventory of anchorless proteins on the colon adenocarcinoma cell surface. Biochim. Biophys. Acta Proteins Proteomics 1764, 1607-1617 (2006). (Pubitemid 44566480)
70. Xing XM, Lai MD, Wang YH, Xu EP, Huang Q. Overexpression of glucose-regulated protein 78 in colon cancer. Clin. Chim. Acta 364, 308-315 (2006). (Pubitemid 43120660)
71. Roessler M, Rollinger W, Palme S et al. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res. 11, 6550-6557 (2005). (Pubitemid 41338994)
72. Roessler M, Rollinger W, Mantovani- Endl L et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics 5, 2092-2101 (2006). (Pubitemid 44817021)
73. Kim H, Kang HJ, You KT et al. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 6, 3466-3476 (2006). (Pubitemid 43886162)
74. Chen WS, Chang HY, Li CP, Liu JM, Huang TS. Tumor b-1,4- galactosyltransferase IV overexpression is closely associated with colorectal cancer metastasis and poor prognosis. Clin. Cancer Res. 11, 8615-8622 (2005).
75. Larriba MJ, Casado-Vela J, Pendas- Franco N et al. Novel Snail1 target proteins in human colon cancer identified by proteomic analysis. PloS ONE 5, E10221 (2010).
76. Renert AF, Leprince P, Dieu M et al. The proapoptotic C16-ceramide-dependent pathway requires the death-promoting factor Btf in colon adenocarcinoma cells. J. Proteome Res. 8, 4810-4822 (2009).
77. Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 340, 783-795 (2004). (Pubitemid 38829638)
78. Kim HJ, Kang HJ, Lee H et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J. Proteome Res. 8, 1368-1379 (2009).
79. Lambert O, Cavusoglu N, Gallay J et al. Novel organization and properties of annexin 2-membrane complexes. J. Biol. Chem. 279, 10872-10882 (2004). (Pubitemid 38401577)
80. Melle C, Ernst G, Schimmel B, Bleul A, von Eggeling F. Colon-derived liver metastasis, colorectal carcinoma, and hepatocellular carcinoma can be discriminated by the Ca2+-binding proteins S100A6 and S100A11. PloS ONE 3, E3767 (2008).
81. Melle C, Ernst G, Schimmel B et al. Discovery and identification of a-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 129, 66-73 (2005). (Pubitemid 41002043)
82. Brunagel G, Vietmeier BN, Bauer AJ, Schoen RE, Getzenberg RH. Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res. 62, 2437-2442 (2002). (Pubitemid 34411729)
83. Konety BR, Nguyen TS, Brenes G et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J. Urol. 164, 634-639 (2000). (Pubitemid 30637591)
84. Miller TE, Beausang LA, Winchell LF, Lidgard GP. Detection of nuclear matrix proteins in serum from cancer-patients. Cancer Res. 52, 422-427 (1992).
85. Walgenbach-Brunagel G, Burger B, Leman ES et al. The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer. J. Cell. Biochem. 104, 286-294 (2008).
86. Caldwell RL, Caprioli RM. Tissue profiling by mass spectrometry - a review of methodology and applications. Mol. Cell. Proteomics 4, 394-401 (2005). (Pubitemid 40590559)
87. Chaurand P, Norris JL, Cornett DS, Mobley JA, Caprioli RM. New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. J. Proteome Res. 5, 2889-2900 (2006). (Pubitemid 44749207)
88. Mazzanti R, Solazzo M, Fantappie O et al. Differential expression proteomics of human colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G1329-G1338 (2006). (Pubitemid 43788316)
89. Pei HP, Zhu H, Zeng S et al. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J. Proteome Res. 6, 2495-2501 (2007). (Pubitemid 47122346)
90. Hanash S. It takes a village to develop biomarkers. J. Proteome Res. 6, 3362 (2007). (Pubitemid 47522721)
91. Ruginis T, Taglia L, Matusiak D, Lee BS, Benya RV. Consequence of gastrin-releasing peptide receptor activation in a human colon cancer cell line: a proteomic approach. J. Proteome Res. 5, 1460-1468 (2006). (Pubitemid 43865814)
92. Dippold W, Wittig B, Schwaeble W, Mayet W, Zumbuschenfelde KH. Expression of intercellular-adhesion molecule-1 (Icam-1, Cd54) in colonic epithelial-cells. Gut 34, 1593-1597 (1993). (Pubitemid 23341854)
93. Gaedtke L, Thoenes L, Culmsee C, Mayer B, Wagner E. Proteomic analysis reveals differences in protein expression in spheroid versus monolayer cultures of low-passage colon carcinoma cells. J. Proteome Res. 6, 4111-4118 (2007). (Pubitemid 350158489)
94. Nam MJ, Kee MK, Kuick R, Hanash SM. Identification of defensin a 6 as a potential biomarker in colon adenocarcinoma. J. Biol. Chem. 280, 8260-8265 (2005). (Pubitemid 40349727)
95. Lawlor K, Nazarlan A, Lacomis L, Tempst P, Villanueva J. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J. Proteome Res. 8, 1489-1503 (2009).
96. Shi HJ, Stubbs R, Hood K. Characterization of de novo synthesized proteins released from human colorectal tumour explants. Electrophoresis 30, 2442-2453 (2009).
97. Wu CC, Chen HC, Chen SJ et al. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 8, 316-332 (2008).
98. Llanos S, Efeyan A, Monsech J, Dominguez O, Serrano M. A high-throughput loss-of-function screening identifies novel p53 regulators. Cell Cycle 5, 1880-1885 (2006). (Pubitemid 44435334)
99. Volmer MW, Stuhler K, Zapatka M et al. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 5, 2587-2601 (2005). (Pubitemid 40966486)
100. Rangiah K, Tippornwong M, Sangar V et al. Differential secreted proteome approach in murine model for candidate biomarker discovery in colon cancer. J. Proteome Res. 8, 5153-5164 (2009).
101. Yang X, Lazar IM. MRM screening/ biomarker discovery with linear ion trap MS: a library of human cancer-specific peptides. BMC Cancer 9, 96 (2009).
102. Makawita S, Diamandis EP. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem. 56(2), 212-222 (2010).
103. Chen Y, Lin P, Qiu SM et al. Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int. J. Oncol. 30, 1137-1144 (2007).
104. Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin. Cancer Res. 6, 505-511 (2000). (Pubitemid 30111471)
105. Verberkmoes NC, Russell AL, Shah M et al. Shotgun metaproteomics of the human distal gut microbiota. ISME J. 3, 179-189 (2009).
106. Ang C, Rothacker J, Patsiouras H, Burgess A, Nice E. Murine fecal proteomics: a model system for the detection of potential biomarkers for colorectal cancer. J. Chromatogr. A 1217, 3330-3340 (2010).
107. Karl J, Wild N, Tacke M et al. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin. Gastroenterol. Hepatol. 6, 1122-1128 (2008).
108. Kaiser J. Cancer - first pass at cancer genome reveals complex landscape. Science 313, 1370 (2006).
109. Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006). (Pubitemid 44571966)
110. Kilpelainen TP, Tammela TL, Maattanen L et al. False-positive screening results in the Finnish prostate cancer screening trial. Br. J. Cancer 102, 469-474 (2010).
111. Gigerenzer G. Making sense of health statistics. Bull. World Health Organ. 87, 567 (2009).
112. Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J. Natl. Cancer Inst. 101, 1216-1220 (2009).